PostEra vs McKesson

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (75 vs 79)
PostEra logo

PostEra

LeaderHealthcare

General

SF AI medicinal chemistry platform with $1B+ pharma partnerships; $610M Pfizer expansion Jan 2025 ($12M upfront) hitting preclinical milestones 40% faster; $26M raised competing with Schrödinger for AI small molecule and ADC drug design.

AI VisibilityBeta
Overall Score
B75
Category Rank
#77 of 596
AI Consensus
87%
Trend
stable
Per Platform
ChatGPT
73
Perplexity
76
Gemini
77

About

PostEra is a San Francisco-based AI-powered medicinal chemistry and drug discovery platform — backed with $26 million in total funding — providing pharmaceutical companies with the Proton AI platform for designing new small molecules and antibody-drug conjugates (ADCs) that accelerates the design-make-test cycle in drug discovery through machine learning models trained on medicinal chemistry synthesis rules and structure-activity relationships. PostEra has secured over $1 billion in total AI drug discovery partnerships including a $610 million collaboration expansion with Pfizer in January 2025 ($12 million upfront payment plus milestone payments and tiered royalties), and a partnership with Amgen and NIH. In the Pfizer collaboration, PostEra hit preclinical development milestones 40% faster than Pfizer anticipated, validating the AI acceleration thesis at pharmaceutical scale.

Full profile
McKesson logo

McKesson

LeaderHealthcare

General

Largest US pharmaceutical distributor with $308.9B FY2024 revenue; thin-margin distribution triopoly with Cencora and Cardinal Health; US Oncology Network (1,700+ oncologists) is highest-margin segment.

AI VisibilityBeta
Overall Score
B79
Category Rank
#26 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
82
Perplexity
76
Gemini
82

About

McKesson Corporation is the largest pharmaceutical distributor in North America and a leading healthcare services company, founded in 1833 in New York City by John McKesson and Charles Olcott and now headquartered in Irving, Texas, trading on NYSE (MCK). The company reported approximately $308.9 billion in revenues for fiscal year 2024 (ending March 31, 2024) under CEO Brian Tyler, making it one of the highest-revenue companies in the United States—though the vast majority of revenues represent pass-through pharmaceutical product costs distributed to approximately 40,000 pharmacies, health systems, and medical providers across North America. McKesson operates through four segments: U.S. Pharmaceutical (the dominant distribution engine), Prescription Technology Solutions (pharmacy benefits technology including CoverMyMeds e-prior authorization), Medical-Surgical Solutions (physician office and extended care medical supply distribution), and International (primarily Canadian distribution through McKesson Canada).

Full profile

AI Visibility Head-to-Head

75
Overall Score
79
#77
Category Rank
#26
87
AI Consensus
77
stable
Trend
stable
73
ChatGPT
82
76
Perplexity
76
77
Gemini
82
78
Claude
85
78
Grok
77

Key Details

Category
General
General
Tier
Leader
Leader
Entity Type
company
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.